- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07546448
Electrolitos Séricos y Nefropatía Inducida por Contraste en Pacientes con Accidente Cerebrovascular Isquémico Agudo Sometidos a Tratamiento Endovascular
El Impacto de los Niveles de Electrolitos Séricos en el Riesgo de Nefropatía Inducida por Contraste en Pacientes con Accidente Cerebrovascular Isquémico Agudo Sometidos a Terapia Endovascular
This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).
Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.
In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.
The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.
Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.
Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.
In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.
Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.
The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Outside of the US
-
Diyarbakır, Outside of the US, Turquía (Türkiye), 21070
- Fatma Acil
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.
The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.
Descripción
Inclusion Criteria:
- Adults aged 18 years or older
- Patients diagnosed with acute ischemic stroke
- Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
- Patients with a baseline NIHSS score of 6 or higher
- Patients who received iodinated contrast medium during the endovascular procedure
- Patients managed under general anesthesia
- Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury
Exclusion Criteria:
- Age younger than 18 years
- Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
- APACHE score greater than 25 at the time of the procedure
- Known allergy or hypersensitivity to iodinated contrast media
- Exposure to iodinated contrast media within the previous 2 weeks
- Use of nephrotoxic medications within the previous 2 weeks
- History of myocardial infarction or previous stroke
- Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
- Systemic steroid use at the time of the procedure
- Incomplete medical records or missing laboratory data required for evaluation of CI-AKI
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: RETROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
CI-AKI Group
Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development. |
No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development. |
|
Non-CI-AKI Group
Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements. |
No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of contrast-induced acute kidney injury (CI-AKI)
Periodo de tiempo: Within 48-72 hours after contrast exposure
|
CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria. |
Within 48-72 hours after contrast exposure
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
90-day mortality
Periodo de tiempo: Within 90 days after endovascular therapy
|
All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI). |
Within 90 days after endovascular therapy
|
|
Dialysis dependency in patients with CI-AKI
Periodo de tiempo: Within 90 days after endovascular therapy
|
Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI) |
Within 90 days after endovascular therapy
|
|
Change in serum creatinine
Periodo de tiempo: Baseline to 48-72 hours after endovascular therapy
|
Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure. |
Baseline to 48-72 hours after endovascular therapy
|
|
Association between serum electrolyte levels and CI-AKI
Periodo de tiempo: Baseline (pre-procedural measurements)
|
Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury. |
Baseline (pre-procedural measurements)
|
|
Length of hospital stay
Periodo de tiempo: Within 90 days after endovascular therapy
|
Total duration of hospitalization in days, compared between patients with and without CI-AKI. |
Within 90 days after endovascular therapy
|
|
Inflammatory markers and CI-AKI relationship
Periodo de tiempo: Baseline (pre-procedural measurements)
|
Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI. |
Baseline (pre-procedural measurements)
|
|
Change in estimated glomerular filtration rate (eGFR)
Periodo de tiempo: Baseline to 48-72 hours after endovascular therapy
|
Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure |
Baseline to 48-72 hours after endovascular therapy
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Insuficiencia renal
- Carrera
- Accidente cerebrovascular isquémico
- Lesión renal aguda
Otros números de identificación del estudio
- 27.012.2026-37
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .